Alzheimer's Disease Trial, Recruiting NCT03761381 Sponsor: Oregon Health and Science University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT03761381
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For people with dementia:

  • A doctor has confirmed a diagnosis of probable Alzheimer's disease
  • The dementia is mild, based on results from standard memory and thinking tests (confirm with trial site for specific scores)
  • The person is older than 55 years
  • The person is able to follow the study procedures
  • The person has vision of at least 20/400 (with glasses or contacts if needed) in at least one eye
  • The person has a legally authorised representative who can sign the consent form and attend the study visit with them

For people without dementia (comparison group):

  • The person is older than 55 years
  • The person is able to follow the study procedures
  • The person is able to hold their gaze steady during the eye-imaging procedure
  • The person has vision of at least 20/40 (with glasses or contacts if needed) in at least one eye
  • The person has no diagnosis of dementia, based on standard memory and thinking tests (confirm with trial site for specific scores)

Who may not be able to join:

  • People who have a neurological condition unrelated to Alzheimer's disease that affects the brain or nervous system, such as multiple sclerosis or Parkinson's disease
  • People whose eye examination in the past year showed eye diseases that could affect the study results, such as glaucoma, diabetic eye disease, or high blood pressure-related eye damage
  • People who have cloudiness in the eye — such as cataracts, corneal scarring, or cloudiness in the gel inside the eye — that could interfere with retinal imaging
  • People who have had previous eye surgery, except for straightforward cataract removal with a standard lens implant
  • People who are unable to hold their gaze steady during the eye scan, or who are unable to give informed consent
  • People whose prescription glasses strength falls outside a certain range, or who have a significant level of astigmatism (confirm with trial site for specific measurements)
  • People who have had diabetes for more than 10 years, or whose recent blood sugar control levels were above a certain threshold in the 180 days before the eye scan
  • People with uncontrolled high blood pressure above a certain level (confirm with trial site for specific readings)
  • People with an irregular heartbeat, or a heart rate outside the range of 50 to 110 beats per minute
  • People who are pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: David Huang, MD, PhD, Oregon Health and Science University

Phone: 503-494-4351

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
14 September 2018
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Retinal amyloid protein detection

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov